Retiro De Equipo (Recall) de STALORAL and PHOSTALSTALORAL (range of sublingual solutions of allergen extracts for allergen immunotherapy)

Según Department of Health, Therapeutic Goods Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Australia que fue producido por Stallergenes Australia Pty Ltd.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
    Recall
  • ID del evento
    RC-2015-RN-01213-1
  • Clase de Riesgo del Evento
    Class I
  • Fecha de inicio del evento
    2015-12-15
  • País del evento
  • Fuente del evento
    DHTGA
  • URL de la fuente del evento
  • Notas / Alertas
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notas adicionales en la data
  • Causa
    Stallergenes australia is recalling the above medicines shipped from the stallergenes antony (france) plant after august 13, 2015. this decision has been made after identification by the french health authority, ansm that the implementation of a new it system on 13 august 2015 could lead to these medicines having incorrect labelling that could result in incorrect dosing. this issue has also caused operational disruptions and supply shortages. any medicines manufactured before 13 august 2015 are not affected and can be used. if the dosage for these medicines is incorrect, there is a potential for inadequate treatment, excessive dosage and/or allergic reaction. as of 16 december 2015, there have been no reports of adverse events in australia or outside of france associated with this issue.
  • Acción
    Stellergenes Australia is advising users to return any unsed stock to the wholesaler for return to Stallergenes. For further information, please see http://www.tga.gov.au/alert/staloral-and-phostal This action has been closed-out on 05/09/2016.

Device

  • Modelo / Serial
    STALORAL and PHOSTALSTALORAL (range of sublingual solutions of allergen extracts for allergen immunotherapy) Multiple Product Codes and Lot/batch numbers affectedPHOSTAL (European Dust Mite (D. Pteronvssinus) suspension for injectionProduct Code: 400007276Lots numbers: 2000277946 & 2000577822
  • Manufacturer

Manufacturer